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Abstract
Alpha‐1‐acid glycoprotein (AGP) is a major acute‐phase protein. Biosynthesis of 
AGP increases markedly during inflammation and infection, similar to nitric oxide 
(NO) biosynthesis. AGP variant A (AGP) contains a reduced cysteine (Cys149). 
Previously, we reported that S‐nitrosated AGP (SNO‐AGP) synthesized by reaction 
with a NO donor, possessed very strong broad‐spectrum antimicrobial activity 
(IC50 = 10
−9‐10−6 M). In this study, using a cecal ligation and puncture animal 
model, we confirmed that AGP can be endogenously S‐nitrosated during infection. 
Furthermore, we examined the antibacterial property of SNO‐AGP against multid-
rug‐resistant Klebsiella pneumoniae and Pseudomonas aeruginosa to investigate the 
involvement of SNO‐AGP in the host defense system. Our results showed that SNO‐
AGP could inhibit multidrug efflux pump, AcrAB‐TolC, a major contributor to bac-
terial multidrug resistance. In addition, SNO‐AGP decreased biofilm formation and 
ATP level in bacteria, indicating that SNO‐AGP can revert drug resistance. It was 
also noteworthy that SNO‐AGP showed synergistic effects with the existing antibiot-
ics (oxacillin, imipenem, norfloxacin, erythromycin, and tetracycline). In conclu-
sion, SNO‐AGP participated in the host defense system and has potential as a novel 
agent for single or combination antimicrobial therapy.
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1 |  INTRODUCTION
While antimicrobial resistance emerges rapidly, unfortu-
nately new antimicrobial agent discovery progresses very 
slowly. Due to the uncontrolled large quantity use of antibiot-
ics, infections by resistant bacteria, such as methicillin‐resis-
tant Staphylococcus aureus (MRSA) and multidrug‐resistant 
Streptococcus pneumoniae, are increasing. On the other 
hand, Klebsiella pneumoniae is the causative bacterium for 
respiratory infection, urinary tract infection, liver/biliary 
tract infection, septicemia, meningitis, and peritonitis. The 
second‐ and third‐generation cephalosporin antibiotics, and 
new quinolone antibiotics have been used to treat infections 
caused by K. pneumoniae, but with suboptimal therapeutic 
effect. Lately, the presence of extended‐spectrum beta‐lact-
amase–producing K. pneumoniae1-3 and carbapenemase‐pro-
ducing K. pneumoniae–resistant to carbapenem antibiotics 
and beta‐lactam antibiotics have been reported.4-6
Furthermore, multidrug‐resistant Pseudomonas aeru-
ginosa is an increasing concern for clinicians,7 owing to a 
broad resistance of the bacteria to not only beta‐lactam but 
also carbapenems, quinolones, aminoglycosides antibiot-
ics.6,8 Furthermore, this drug‐resistant P. aeruginosa readily 
infects patients with hematologic malignancy or other solid 
cancer, highly immunocompromised patients such as bone 
marrow or organ transplant patients, eventually leads to sep-
sis and pneumonia that become refractory with poor prog-
nosis.9 In view of the above situations, development of new 
antibacterial agents as well as highly effective treatment strat-
egy such as combination of synergistic antimicrobial agents 
is desirable.
Nitric oxide (NO) plays a crucial immunological role as a 
broad‐spectrum antimicrobial agent in various infections.10-12 
However, NO is highly reactive with a short biological half‐
life. Therefore, a NO carrier or NO‐generating agent needs 
to be developed for clinical application of NO as an antimi-
crobial drug. It is well known that S‐nitrosothiols, a stable 
NO reservoir, have a 102‐ to 103‐fold stronger antimicrobial 
activity than NO alone.13,14 Hence, S‐nitrosothiols could 
be developed into a stable NO‐related antimicrobial drug. 
Interestingly, delamanid, a new antituberculosis medication, 
possesses the proposed mechanism of action involving intra-
cellular NO release.15
Alpha‐1‐acid glycoprotein (AGP), an acute‐phase protein, 
is mainly produced in the liver. It is also produced by immune 
cells, such as monocytes and macrophages, primarily during 
inflammation, resulting in locally high AGP concentrations at 
inflammatory sites. In most individuals, AGP is a mixture of 
two main genetic variants, F1*S and A. While F1*S variants 
do not possess any free cysteine residue, variant A has one re-
duced cysteine residue at position 149 (Cys149).16 Although it 
is known that Cys149 of AGP is a binding site for copper, the 
biological roles of Cys149 are unclear. All these findings led 
us to hypothesize that AGP could acquire antibacterial activity 
through S‐nitrosation and may be a suitable NO carrier for use 
as an infectious disease therapeutic agent.
Our previous report demonstrated that (a) Cys149 of AGP 
could be exogenously S‐nitrosated by NO donor in vitro, (b) S‐
nitrosated AGP (SNO‐AGP) strongly possessed a broad‐spec-
trum antimicrobial activity (IC50 = 10
−9‐10−6 M) in vitro, and 
(c) exogenous SNO‐AGP exhibited superior antibacterial ac-
tivity in vivo in cecal ligation and puncture (CLP) model mice 
and significantly improved their survival.14 However, it was 
unknown whether AGP could be endogenously S‐nitrosated in 
vivo.
In this study, we demonstrated that the concentration of 
AGP, as well as that of NO, increased remarkably during bac-
terial infection. In this context, we further attempted to detect 
the SNO‐AGP during bacterial infection in CLP model mice. 
Finally, we evaluated the functions of SNO‐AGP as antibac-
terial agent and chemical sensitizer against multidrug‐resis-
tant K. pneumoniae and P. aeruginosa.
2 |  MATERIALS AND METHODS
2.1 | Materials
Lyophilized AGP, methyl methanethiosulfonate (MMTS), dith-
iothreitol (DTT), and glutathione were purchased from Sigma‐
Aldrich (St. Louis, MO). NaNO3 was obtained from Nacalai 
Tesque (Kyoto, Japan). Diethylenetriaminepentaacetic acid 
(DTPA) and S‐nitorsoglutathione (GSNO) were obtained from 
Dojindo Laboratories (Kumamoto, Japan). N‐[6‐(Biotinamido)
hexyl]‐3′‐(2′‐pyridyldithio) propionamide (biotin‐HPDP) was 
obtained from Pierce (Rockford, IL). Other chemicals were of 
highest grade commercially available.
2.2 | Preparation of SNO‐AGP
First, to reduce Cys149 of AGP, AGP was treated with DTT 
in potassium phosphate buffer (PPB) pH 7.4, for 5 minutes at 
37°C, as reported previously.14 After removal of excess DTT 
by gel filtration (PD‐10 Desalting Columns; GE Healthcare 
Japan, Tokyo, Japan), DTT‐treated AGP (300 µM) was reacted 
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with 3 mM GSNO in PPB containing 1 mM DTPA, pH 8.0, for 
30 minutes at 37°C. Then, the excess GSNO was removed from 
SNO‐AGP solution by PD‐10 Desalting Columns, and was con-
centrated by ultrafiltration; it was stored at −80°C until use. The 
S‐nitroso moiety of SNO‐AGP was quantified by the HPLC 
method,10 and was found to be 0.32 ± 0.06 mol SNO/mol AGP.
2.3 | Preparation of the CLP Model and 
detection of SNO‐AGP
Bacterial infection was induced by CLP; male ICR mice un-
derwent CLP according to a previously reported method.17 
This animal experiments were conducted in accordance 
with the ethical standards of the Institutional Animal 
Care and Use Committee of the University of Tokushima 
(T28‐39). Male ICR outbred mice greater than 5 weeks 
of age (25‐30 g). Blood samples (0.3 mL) from surviving 
mice were collected from the tail vein at 0, 3, 6, 9, 12, 
and 24 hours after the puncture. Nitrate (NO3
−) levels of 
these serums were measured using an EiCOM ENO‐20 
NOx analyzer (EiCOM, Kyoto, Japan). NaNO3 solutions 
were used to prepare a standard curve. The serum was col-
lected from the tail vein at 12 by centrifugation (1500× g, 
5 minutes, 4°C). Protein concentrations were adjusted to 
0.5 mg/mL, followed by treatment with MMTS to block 
free SH, according to a previously reported method with 
minor modifications.18 To block free SH groups on the 
protein without affecting the disulfide bonds, 4 volumes 
of blocking buffer [225 mM HEPES (pH 7.7), 0.9 mM 
EDTA, 0.09 mM Neocuproine, 2.5% SDS, and 20 mM 
MMTS] were added. The resulting solutions were agitated 
for 20 minutes at 50°C. Proteins were then recovered by 
precipitation with acetone (final concentration, 50%), and 
the precipitates were resuspended in 0.1 mL of HENS 
buffer (protein concentration, 10 mg/mL). To this protein 
solution, 0.1 mL of biotin‐HPDP (4 mM) in N,N‐dimethyl-
formamide and 0.1 mL of aqueous ascorbate (0 or 1 mM) 
with 100 µM CuCl were added, and the mixture was incu-
bated for 1 hour at 25°C. Proteins were again recovered 
via acetone precipitation. To detect S‐nitrosated proteins 
labeled with HPDP‐biotin, western blot was carried out 
using peroxidase‐conjugated anti‐biotin antibodies.
2.4 | Calculation of IC50 for antibiotics and 
S‐nitrosated proteins against multidrug‐
resistant bacteria
Antibacterial activity against multidrug‐resistant gram‐nega-
tive bacteria K. pneumoniae MGH78578 and P. aeruginosa 
PAO 1 was evaluated according to a previously reported 
method with slight modification.14 Oxacillin, cefmetazole, imi-
penem, norfloxacin, erythromycin, kanamycin, tetracycline, 
chloramphenicol, SNO‐AGP, and S‐nitrosated human serum 
albumin (SNO‐HSA) were used as antimicrobial agents. For 
the cultivation, M9 supplemented with 0.1% yeast extract was 
used. In the above medium, K. pneumoniae MGH78578 or P. 
aeruginosa PAO 1 were prepared to OD630 = 0.050 ± 0.009 
and used for the experiment. Each antimicrobial substance 
was added to the medium and reacted at 37°C for 9 hours. The 
turbidity (OD630) was measured, and the bacterial growth (%) 
was calculated by comparing with the control (PBS) group.
2.5 | Combination effect of antibacterial 
agent and SNO‐AGP in multidrug‐
resistant bacteria
A multidrug‐resistant strain of K. pneumoniae MGH78578 was 
grown in M9 medium and adjusted to OD630 = 0.051 ± 0.01. 
Each concentration of SNO‐AGP was added and grown in M9 
medium at 37°C for 5 hours (OD630 = 0.2‐0.3). Thereafter, it 
was washed three times with M9 medium by centrifugation 
(10,000× g, 2 minutes) and used for the experiment. Four mil-
limolar lactate was added to the pellets, and antimicrobial agents 
with ¼ × IC50 concentrations were also added. As antimicrobial 
agents, oxacillin, cefmetazole, imipenem, norfloxacin, eryth-
romycin, tetracycline, chloramphenicol, and kanamycin were 
used. After incubation at 37°C for 6 hours, the turbidity (OD630) 
was measured, and the bacterial growth (%) was calculated by 
comparing with the control (PBS) group. For the determination 
of synergistic effect, the isobologram method was used.19
2.6 | Effect of SNO‐AGP on 
biofilm formation
The biofilm was prepared using a 96‐well microplate (Cellstar 
96 well cell culture plate, greiner bio‐one, Frickenhausen, 
Germany). K. pneumoniae was grown in M9 medium and 
adjusted to OD630 in each well of a 96‐well microplate. The 
biofilm formation was confirmed from 9 hours after culture. 
Therefore, SNO‐AGP was added to the culture supernatant, 
and the cells were statically cultured at 37°C for 9, 24, or 
48 hours. After culturing, the medium was gently removed, 
and the remaining on the well and bottom was defined as a 
biofilm. After culturing, the biofilm was stained with 200 µL 
of 2% (w/v) crystal violet aqueous solution for 30 minutes. 
This method is a quantitative method utilizing the primary 
correlation between the adsorption amount of crystal violet 
dye and the dry weight of biofilm formed on the well and bot-
tom.19 Then, the crystal violet solution was gently removed, 
sterilized water (250 µL) was added, pipetted 10 times, and 
the water was removed. This wash step was repeated twice. 
Immediately after washing, 200 µL of 95% ethanol was added 
and decolorized by allowing to stand at 25°C for 30 minutes. 
Ethanol (100 µL) in the supernatant was transferred to an-
other 96‐well microplate and the biofilm was determined by 
measuring the absorbance at 570 nm.
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2.7 | Effect of SNO‐AGP on substrate 
accumulation of multidrug efflux pump
A multidrug‐resistant strain of K. pneumoniae MGH 
78578 was grown in M9 medium and adjusted to 
OD630 = 0.050 ± 0.008. Each concentration of SNO‐AGP 
was added to the medium and grown in M9 medium at 37°C 
for 5 hours (OD630 = 0.2‐0.3). Thereafter, it was washed 
three times with M9 medium by centrifugation (10 000× g, 
2 minutes) and used for the experiment. Four millimolar 
lactate and 100 μM carbonyl cyanide m‐chlorophenyl hydra-
zone (CCCP) as energy sources of multidrug efflux pump 
were added. Then, 1 mM norfloxacin, 20 μM EtBr, and/or 
20 μM rhodamine 6G as substrates of multidrug efflux pump 
were added, incubated at 25°C for 15 min, and then wash 
three times by the medium (10 000× g, 2 minutes). The 
measurement was performed at an excitation wavelength of 
485 nm and a emission wavelength of 535 nm. To identify 
types of multidrug efflux pump contributed to substrate ac-
cumulation, multidrug efflux pump AcrB‐deficient strains 
(K. pneumoniae SKY2/pSTV28) and AcrB‐overexpressed 
strains (K. pneumoniae SKY2/pKAC28M) were also used 
as AcrAB‐knockout and ‐introduced stains, respectively.20,21
2.8 | Measurement of ATP level in bacteria
The BacTiter‐Glo™ Microbial Cell Viability Assay 
(Promega, Madison, WI) was used according to the manu-
facturer’s instructions. After reacting K. pneumoniae with 
SNO‐AGP at 37°C, an equal amount of reagent was added to 
the culture medium and incubated at 25°C for 5 minutes, then 
luminescence was measured using a multi‐microplate reader. 
The measurement was adjusted by the number of bacteria.
2.9 | Detection of intracellular NO and 
reactive oxygen species (ROS) in bacteria
K. pneumoniae was grown to OD630 = 0.050 ± 0.008 in M9 
medium, and each SNO‐AGP was added to the medium and 
reacted at 37°C for 7 hours. Thereafter, DAF‐FMDA (for NO) 
or CM‐H2DCFDA (for ROS) was added and reacted at 37°C 
for 1 hour, then the supernatant was removed by centrifuga-
tion (10 000× g, 2 minutes). The bacteria was resuspended 
in M9 medium, SPECTRA FLUOR XFluor 4 (TECAN) was 
used for monitoring at an excitation wavelength of 485 nm 
and a emission wavelength of 535 nm.
2.10 | Dot‐blot analysis of nitrotyrosine on 
bacterial membrane
K. pneumoniae was treated with SNO‐AGP at 37°C for 30 min-
utes. Nitrative stress derived from AGP was assessed by dot‐
blot analysis of a bacterial membrane. The SNO‐AGP‐treated 
bacteria was lysed using LIPA buffer (adjust to1 mg/mL), 
and the lysed bacteria (10 µL) was doted to a nitrocellulose 
membrane, and dried for 15 minutes at 60°C. For detection of 
nitrated protein, a mouse monoclonal 3‐nitrotyrosine antibody 
was used at a dilution of 1:1,000. Densitometric quantification 
of the dots was performed using ImageJ software.
2.11 | Statistical Analysis
Data are shown as means ± SD for the indicated number of ani-
mals. Significant differences among each group were determined 
by means of the two‐tailed unpaired Student’s t test. A probabil-
ity P value of <0.05 was said to indicate statistical significance.
3 |  RESULTS
3.1 | Formation of SNO‐AGP during CLP‐
induced bacterial infection
During bacterial infection, inducible nitric oxide synthase 
(iNOS) and AGP were induced. We demonstrated that bacterial 
F I G U R E  1  NO and SNO‐AGP production in mice CLP model. 
(A) Bacterial infection was induced by CLP, Blood samples from 
surviving mice were collected from the tail vein at 0, 3, 6, 9, 12, and 
24 hours after the puncture. Nitrate (NO3
‐) levels of these serums were 
measured using an EiCOM ENO‐20 NOx analyzer. Data are expressed 
as means ± SD (n = 5). **, P ＜ 0.01 compared with at 0 hour after 
the puncture. (B) The serum collected from the tail vein at 12 hours 
after the puncture was collected by centrifugation. AGP and SNO‐AGP 
were detected using western blot and biotin switch assay, respectively. 
Ascorbate (‐) was used as negative control of biotin switch assay and 
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infection model by CLP actually increased the levels of nitrate 
and AGP in serum (Figure 1). We detected SNO‐AGP during 
CLP‐induced infection using a biotin switch assay, which is a 
detection method of S‐nitrosated proteins, suggesting that SNO‐
AGP was endogenously induced during bacterial infection.
3.2 | Antibacterial activity of SNO‐AGP 
against multidrug‐resistant bacteria
We have showed that S‐nitrosated proteins possess anti-
bacterial activity.10 Multidrug‐resistant bacteria K. pneu-
moniae22 and P. aeruginosa23-25 were used to compare the 
antibacterial activity of SNO‐AGP with existing antimi-
crobials (oxacillin, cefmetazole, imipenem, norfloxacin, 
erythromycin, kanamycin, tetracycline, and chlorampheni-
col). IC50 values for each antimicrobial agent against 
multidrug‐resistant bacteria were calculated. The IC50s of 
SNO‐AGP against K. pneumoniae and P. aeruginosa are 
0.06 µM, and 1 µM, respectively (Figure 2 and Table 1). 
Our previous study demonstrated that AGP without NO ad-
dition did not affect bacterial growth.14 These data demon-
strated that SNO‐AGP acts as an endogenous antibacterial 
agent in vivo.
3.3 | Combined effect of various 
antimicrobial agents and SNO‐AGP against 
multidrug‐resistant bacteria
The combined effects of SNO‐AGP with various antimi-
crobial agents were evaluated using K. pneumoniae and P. 
aeruginosa. Each concentration of SNO‐AGP added to the 
medium was combined with or without an antimicrobial 
substance at a concentration of 1/4 of the IC50. The bac-
terial growth of K. pneumoniae and P. aeruginosa were 
significantly inhibited by SNO‐AGP in a concentration‐de-
pendent manner. In addition, the antimicrobial activity of 
SNO‐AGP against K. pneumoniae was further inhibited by 
oxacillin, imipenem, norfloxacin, erythromycin, or tetra-
cycline. On the other hand, the antimicrobial activity of 
SNO‐AGP against P. aeruginosa was also inhibited by ox-
acillin, cefmetazole, imipenem, norfloxacin, erythromycin, 
tetracycline, or chloramphenicol (Figure 3). Tables 2 and 3 
showed combination index (CI) of the results calculated by 
F I G U R E  2  Antibacterial activity of S‐nitrosated proteins 
and antibiotics against (A) Klebsiella pneumoniae MGH78578 (B) 
Pseudomonas aeruginosa PAO1. K. pneumoniae MGH78578 or P. 
aeruginosa PAO 1 were prepared and used for the experiment. Each 
antimicrobial substance was added to the supernatant of the medium 
and reacted at 37°C for 9 hours. The turbidity (OD630) was measured, 
and the bacterial growth (%) was calculated by comparing with the 
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Classification Antibacterial agents K. pneumoniae P. aeruginosa
β‐Lactam Oxacillin 15 15
Cefmetazole 0.012 9
Imipenem 0.002 0.0005
Quinolone Norfloxacin 0.015 0.001
Aminoglycoside Erythromycin 0.6 0.4
Tetracycline 1.2 0.01
Chloramphenicol 1.0 0.1
Macrolide Kanamycin 100 0.7
RS‐NO SNO‐AGP 0.00006 0.001
SNO‐HSA 0.0013 0.025
T A B L E  1  IC50 values for each 
antimicrobial agent against multidrug‐
resistant bacteria
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the statistical analysis method isobologram method. If the 
value of CI = da/Da + db/Db is 1 or less, it is synergistic, 
1 is additive, and if it is 1 or more, it is judged to be antag-
onistic (da, db; respective concentrations in combination 
with drugs a and b; Da, Db: concentrations of a and b alone 
necessary for showing the same effect as in combination). 
These data indicated that SNO‐AGP could synergistically 
enhance the antibacterial activity of a broad‐spectrum an-
timicrobial agent against these two multidrug‐resistant 
bacteria.
3.4 | Effect of SNO‐AGP on 
biofilm formation
Biofilm formation is one of the mechanisms of multidrug 
resistance of bacteria. Biofilm refers to a three‐dimensional 
structure composed of a microbial population attached to the 
surface and extracellular polymeric substance (EPS) produced 
by microorganisms, and microbial cells that formed the bio-
film behave differently from cells in a floating state.26 It has 
been reported that various bacteria can form a biofilm and it 
has also been shown that NO inhibits biofilm formations.27 
Therefore, to further clarify the mechanism of SNO‐AGP 
overcoming multidrug resistance, the effect of SNO‐AGP on 
biofilm formation of K. pneumoniae was evaluated by crystal 
violet method. Figure 4 showed that SNO‐AGP inhibited the 
biofilm formation of K. pneumoniae for at least 48 hours in 
a concentration‐dependent manner (10−8‐10−7 M). Such ef-
fect was not observed by incubation with AGP. These results 
suggest that NO released from SNO‐AGP could strongly in-
hibit biofilm formation through the antimicrobial activity of 
SNO‐AGP.
3.5 | Effect of SNO‐AGP on substrate 
accumulation of multidrug efflux pump
Multidrug efflux pumps were reported as resistance mech-
anism of K. pneumoniae MGH 78578.22,28-31 Hence, we 
hypothesized that SNO‐AGP synergistically enhances the 
activity of a broad spectrum of antibacterial agents by inhib-
iting this multidrug efflux pump. In order to examine this hy-
pothesis, we measured bacterial accumulation of Rhodamine 
6G, ethidium bromide (EtBr), and norfloxacin, which are 
substrates of a multidrug efflux pump, in the presence of 
SNO‐AGP. A significant increase in the cellular fluorescence 





















SNO-AGP (10–9 mol/L) SNO-AGP (10–9 mol/L) SNO-AGP (10–9 mol/L)
SNO-AGP (10–9 mol/L) SNO-AGP (10–9 mol/L) SNO-AGP (10–9 mol/L)































































































































































F I G U R E  3  (Continued)
   | 143ISHIMA et Al.
of SNO‐AGP dependent manner. Moreover, no increase in 
fluorescence intensity was observed when AGP was added 
at the same concentration (Figure 5). These indicated that 
SNO‐AGP could overcome the K. pneumoniae MGH 
78578 resistance via multidrug efflux pumps inhibition. 
Furthermore, the reaction time with SNO‐AGP was varied 
from 0 to 9 hours, and the accumulation of Rhodamine 6G 
was evaluated. At this time, SNO‐AGP was added at a con-
centration of 0.015 μM, which does not exhibit the growth‐
suppressing effect (Supporting information Figure S1). As a 
result, the elevating effect of Rhodamine 6G accumulation by 
SNO‐AGP was observed from 3 hours after incubation and 
lasted until 6 hours, but it disappeared after 9 hours thereafter 
(Supporting information Figure S2), suggesting that effect of 
SNO‐AGP on the activity of multidrug efflux pumps is tran-
siently inhibited.
3.6 | Effect of SNO‐AGP on AcrAB‐TolC 
efflux activity of multidrug efflux pump
K. pneumonia MGH78578 expresses multidrug efflux pump, 
AcrAB‐TolC belonging to RND family, its multidrug resistance 
is known to involve this efflux pump.30 To clarify the effects 
of SNO‐AGP on AcrAB‐TolC, we investigated the accumula-
tion of Rhodamine 6G using AcrAB‐deficient strain (AcrAB‐
knockout stain from K. pneumoniae ATCC10031) compared 
with AcrAB‐introduced strain. As a result, SNO‐AGP could 
increase the Rhodamine 6G fluorescence of AcrAB‐introduced 
stain in a concentration‐dependent manner. On the other hand, 
the Rhodamine 6G fluorescence of AcrAB‐knockout stain was 
not affected by SNO‐AGP treatment (Figure 6). This data in-
dicated that SNO‐AGP increases the accumulation of substrate 
by suppressing multidrug efflux pump AcrAB‐TolC.
F I G U R E  3  Growth inhibitory effect of antibacterial drugs combined with SNO‐AGP on multidrug‐resistant strains. Multidrug‐resistant 
strains of (A) Klebsiella pneumoniae MGH78578 or (B) Pseudomonas aeruginosa PAO1 were grown in M9 medium. Each concentration of 
SNO‐AGP was added to the medium supernatant and grown in M9 medium at 37°C for 5 hours (OD630 = 0.2‐0.3). Thereafter, it was washed three 
times with M9 medium and used for the experiment. Then, ¼ × IC50 concentrations of antimicrobial agents (oxacillin, cefmetazole, imipenem, 
norfloxacin, erythromycin, tetracycline, chloramphenicol, and kanamycin) were added and incubated at 25°C for 15 minutes. After incubation at 
37°C for 6 hours, the turbidity (OD630) was measured and the bacterial growth (%) was calculated by comparing with the control group. Data are 
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3.7 | Effect of SNO‐AGPs on bacterial 
ATP levels
We previously demonstrated that SNO‐AGP possesses a very 
strong antibacterial activity against various bacteria via NO 
transfer to bacteria.14 It is well‐known that NO inhibits cy-
tochrome c oxidase in the electron transport chain, thereby 
decreasing the ATP level in bacteria.31 Therefore, the influ-
ence of SNO‐AGP on ATP level in bacteria was evaluated. 
The results showed that ATP level in bacteria was decreased 
by SNO‐AGP within 2 hours of addition, and it was reduced to 
about 50% after 3 hours (Figure 7A). The inhibitory effect of 
SNO‐AGP was canceled by carboxy‐PTIO which is a NO scav-
enger (Figure 7B). These results suggest that SNO‐AGP could 
reduce the bacterial ATP level in a NO‐dependent manner.
3.8 | Generation of active oxygen species 
(ROS) by SNO‐AGP
The possibility of reactive oxygen species (ROS) gen-
eration by SNO‐AGP via cytochrome c oxidase inhibition 
was analyzed using the ROS detection fluorescent probe 
CM‐H2DCFDA.
32 DAF‐FMDA fluorescence (NO probe) 
increased within 10 minutes, whereas fluorescence inten-
sity of CM‐H2DCFDA increased 30 minutes later (Figure 
8AB) after SNO‐AGP addition. ROS generation in bacte-
ria was also inhibited by carboxy‐PTIO (Figure 8C and D). 
Furthermore, the bacterial growth was negatively correlated 
with both DAF‐FMDA and CM‐H2DCFDA (Figure 9). These 
results suggest that one of the antibacterial mechanisms of 
SNO‐AGP was derived from ATP depletion and ROS gen-
eration induced by the inhibition of cytochrome c oxidase.
3.9 | Nitrotyrosine induced by SNO‐AGP 
in Bacteria
The presence of ROS and NO could induce peroxynitrite 
(ONOO−) in bacteria. The generation of ONOO− can be 
evaluated by detecting the nitration of endogenous proteins 
in bacteria using dot‐blotting analysis. Figure 10 showed that 
SNO‐AGP could induce nitration of whole bacteria proteins 
in a concentration‐dependent manner. This suggests that the 
function of some proteins such as AcrAB‐TolC might be in-
hibited via nitration of active sites.
T A B L E  2  IC50 values and combination index (CI) for each antimicrobial agent against Klebsiella pneumoniae
Antibacterial agents IC50 (mM) Drugs concn (mM) CI
a in the presence of SNO‐AGP at concn (M) of:
0.00781 0.0156 0.0313 0.0625 0.125 0.25 0.5
Oxacillin 15 3.75 0.49 0.51 0.44 0.65 0.97 1.70 3.18
Cefmetazole 0.012 0.003 1.38 1.77 2.74 3.89 4.29 7.86 14.98
Imipenem 0.002 0.0005 0.48 0.44 0.38 0.38 0.28 0.27 0.30
Norfloxacin 0.015 0.00375 0.67 0.68 0.42 0.55 0.48 0.72 0.31 
Erythromycin 0.6 0.15 0.79 0.57 0.58 0.55 0.63 0.43 0.40 
Tetracycline 1.2 0.3 0.49 0.58 0.67 0.54 0.75 0.86 0.93 
Chloramphenicol 1.0 0.25 2.45 2.60 2.34 3.04 5.00 4.13 3.79
Kanamycin 100 25 — 4.55 9.31 1.03 1.51 1.70 3.37
As antimicrobial agents, oxacillin, cefmetazole, imipenem, norfloxacin, erythromycin, tetracycline, chloramphenicol, and kanamycin were used.
aCombination index was calculated by the isobologram method.19 
T A B L E  3  IC50 values and combination index (CI) for each antimicrobial agent against Pseudomonas aeruginosa
Antibacterial agents IC50 (mM) Drugs concn (mM) CI
a in the presence of SNO‐AGP at concn (M) of:
0.00781 0.0156 0.0313 0.0625 0.125 0.25 0.5
Oxacillin 15 3.75 0.73 0.27 0.12 0.14 0.15 0.21 0.25
Cefmetazole 9 2.25 0.67 0.57 0.43 0.28 0.30 0.35 0.45
Imipenem 0.0005 0.000125 1.18 2.09 1.81 0.84 1.04 1.19 1.17
Norfloxacin 0.001 0.00025 1.51 0.75 0.79 0.80 0.75 0.88 0.75 
Erythromycin 0.4 0.10 0.90 0.98 0.64 0.36 0.38 0.35 0.43 
Tetracycline 0.01 0.0025 0.67 0.34 0.38 0.48 0.47 0.32 0.35 
Chloramphenicol 0.1 0.020 0.93 0.97 0.50 0.40 0.40 0.43 0.44
Kanamycin 0.7 0.175 1.45 1.95 2.46 2.40 1.05 1.07 1.66
As antimicrobial agents, oxacillin, cefmetazole, imipenem, norfloxacin, erythromycin, tetracycline, chloramphenicol, and kanamycin were used.
aCombination index was calculated by the isobologram method.19 
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4 |  DISCUSSION
We previously reported that SNO‐AGP kills drug‐resistant 
bacteria and aids survival in sepsis. Subsequently, we dem-
onstrated here two major findings: (a) SNO‐AGP synergisti-
cally enhances the activity of a wide range of antimicrobial 
F I G U R E  4  Quantification of biofilm formation of Klebsiella 
pneumoniae MGH78578 incubated with SNO‐AGP by crystal violet 
staining. Pseudomonas pneumoniae was grown in M9 medium and 
adjusted to OD630 in each well of a 96‐well microplate. SNO‐AGP was 
added to the culture supernatant, and the cells were statically cultured 
at 37°C for 9, 24, or 48 hours. After culturing, the medium was stained 
with 200 µL of 2% (w/v) crystal violet aqueous solution for 30 minutes. 
Immediately after washing, 200 µL of 95% ethanol was added and 
decolorized by allowing to stand at 25°C for 30 minutes. Ethanol (100 
µL) in the supernatant was transferred to another 96‐well microplate 
and the biofilm was determined by measuring the absorbance at 
570 nm. Data are expressed as mean ± SD (n = 3‐20). ***P ＜ 0.001, 



































































F I G U R E  5  Substrate accumulation of multidrug efflux pump 
of Klebsiella pneumoniae MGH78578 incubated with SNO‐AGP. A 
multidrug‐resistant strain of K. pneumoniae MGH 78578 was grown in 
M9 medium. Each concentration of SNO‐AGP or AGP (250 nM) was 
added to the medium supernatant and grown in M9 medium at 37°C. 
for 5 hours (OD630 = 0.2‐0.3). Then, (A) Rhodamine 6G, (B) EtBr, and 
(C) Norfloxacin as substrates of multidrug efflux pump were added, 
incubated at 25°C for 15 minutes, and then wash three times in the 
medium. The measurement was performed at an excitation wavelength 
of 485 nm and a fluorescence wavelength of 535 nm. Data are 







































































146 |   ISHIMA et Al.
agents, and (b) SNO‐AGP could act as an antibacterial agent 
and chemical sensitizer via inhibiting biofilm formation, 
multidrug efflux pump and ATP levels in bacteria. These 
findings indicated that the sensitivity of antimicrobial agents 
that have become ineffective due to multidrug resistance 
could be revived when use in combination with SNO‐AGP. 
However, further in vivo studies are needed to examine 
whether sufficient clinical effect can be obtained in actual 
clinical application.
SNO‐AGP enhanced the antimicrobial activity of inef-
fective antibiotics against K. pneumoniae via mechanisms 
involving inhibitions of biofilm formation (Figure 4) and 
multidrug efflux pump (Figures 5 and 6). Biofilm formation 
inhibition by SNO‐AGP is expected to increase the amount 
of antibiotic reaching the bacteria.33-35 Active efflux of an-
tibiotics by multidrug efflux pumps is also an important 
mechanism in multidrug resistance of bacteria.36 Among 
the multidrug efflux pumps, the multidrug efflux systems 
similar to AcrAB are expressed not only in K. pneumoniae, 
but also in a wide range of gram‐negative multidrug resis-
tance bacteria including E. coli.37-39 AcrAB is composed of 
the inner membrane protein AcrB belonging to the RND 
family40 and the periplasmic lipoprotein AcrA belonging to 
the membrane fusion protein family.41 In cooperation with 
the outer‐membrane channel TolC,42 the AcrAB‐TolC ef-
flux pump is able to transport vectorially a diverse array 
of compounds with little chemical similarity, thus confer-
ring resistance to a broad spectrum of antibiotics using the 
proton (H+) driving force.43,44 The research findings on the 
crystal structure analysis45-47 and expression regulation48-50 
illuminate the basis for drug resistance in numerous patho-
genic bacterial species. However, clinically applicable 
F I G U R E  6  Efflux activities of Rhodamine 6G in AcrAB‐
knockout stain of Klebsiella pneumonia. AcrAB‐knockout strain 
(SKY2/pSTV28, acrAB‐disrupted strain from K. pneumoniae 
ATCC10031) and AcrAB‐introduced strain (SKY2/pKAC28M, 
acrAB‐transformed strain for SKY2/pSTV28) were grown in M9 
medium. Each concentration of SNO‐AGP was added to the medium 
supernatant and grown in M9 medium at 37°C for 5 hours. Then, 
Rhodamine 6G was added, incubated at 25°C for 15 minutes, and then 
washed three times in the medium. The measurement was performed 
at an excitation wavelength of 485 nm and a fluorescence wavelength 
of 535 nm. Data are expressed as mean ± SD (n = 8). ***P ＜ 0.001, 
**P ＜ 0.01, compared with AcrAB‐introduced stain, SNO‐AGP (‐). 




































F I G U R E  7  ATP levels on bacteria after incubation of SNO‐
AGP. After reacting Klebsiella pneumoniae with 250 nM SNO‐AGP 
at 37°C, an equal amount of reagent was added to the medium 
supernatant and incubated at 25°C for 5 min, then ATP level on 
bacteria was measured using the BacTiter‐Glo ™ Microbial Cell 
Viability Assay. Effect of 100 pM Carboxy‐PTIO on SNO‐AGP 
reduction of ATP level in bacteria was also performed. Data are 
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inhibitor of multidrug efflux pumps like AcrAB is still yet 
to be discovered. Hence, SNO‐AGP has high potential as the 
first multidrug efflux pump inhibitor to overcome the mul-
tidrug resistance of a wide range of gram‐negative bacteria 
expressing AcrAB‐TolC. Therefore, further human studies 
are needed to examine whether inhibitor of multidrug efflux 
pumps like AcrAB can be affected on the effect of other 
antibiotics against multidrug resistance bacterial infection. 
In addition, Tables 2 and 3 showed that antibacterial activity 
of some antibiotics such as kanamycin could be reduced by 
SNO‐AGP. The inhibitory mechanism of some antibiotics 
such as kanamycin by SNO‐AGP should be clarified in near 
future.
The antibiotics whose activity was enhanced by SNO‐
AGP against K. pneumoniae, oxacillin, norfloxacin, eryth-
romycin, and tetracycline have been shown to be a substrate 
of AcrAB‐TolC.20 In contrast, cefmetazole, kanamycin, 
and chloramphenicol that are not considered to be a sub-
strate of AcrAB‐TolC, did not exhibit the synergistic ef-
fect. Although imipenem is not a substrate of AcrAB‐TolC, 
an enhanced activity by SNO‐AGP combination was ob-
served. Porin pore expressed on the outer membrane of 
bacteria involved as a major resistance mechanism against 
imipenem. Previous reports showed that low expression of 
porin pore inhibits the uptake of imipenem into the bacte-
ria.51,52 It is possible that SNO‐AGP affects the expression 
of porin pore, thereby increasing the uptake of imipenem 
and enhancing the activity, but detailed investigation is 
needed in the future.
Emergence of various multidrug‐resistant bacteria caus-
ing resistant bacterial infection is a very critical clinical 
problem. SNO‐AGP was induced in bacterial‐infected mice, 
indicated that SNO‐AGP is one of the host defense mech-
anism. To clarify whether SNO‐AGP acts as host defense 
factor in human, detection of SNO‐AGP in human plasma 
during various bacterial infection should be further investi-
gated. In conclusion, SNO‐AGP, a novel inhibitor of multi-
drug efflux pumps, is highly promising as a new drug for 
designing a new therapeutic strategy to overcome multidrug 
resistance bacterial infection conundrum.
F I G U R E  8  Intraceller NO and ROS production in bacteria stimulated by SNO‐AGP. Klebsiella pneumoniae was prepared in M9 medium, 
and each SNO‐AGP was added to the medium supernatant and reacted at 37°C for 7 hours. Thereafter, DAF‐FMDA (for NO) or CM‐H2DCFDA 
(for ROS) was added and reacted at 37°C for 1 hour. SPECTRA FLUOR XFluor 4 (TECAN) was used for monitoring at an excitation wavelength of 
485 nm and a fluorescence wavelength of 535 nm. Effect of Carboxy‐PTIO on the intracellular NO and ROS production stimulated by SNO‐AGP was 
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